WuXi Biologics (Cayman) has a quick ratio of 3.22. It generally indicates good short-term financial strength.
The historical rank and industry rank for WuXi Biologics (Cayman)'s Quick Ratio or its related term are showing as below:
MEX:2269N'
s Quick Ratio Range Over the Past 10 Years
Min: 0.94 Med: 2.74 Max: 4.18
Current: 3.22
During the past 12 years, WuXi Biologics (Cayman)'s highest Quick Ratio was 4.18. The lowest was 0.94. And the median was 2.74.
MEX:2269N's Quick Ratio is ranked worse than 53.53% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs MEX:2269N: 3.22
WuXi Biologics (Cayman) (MEX:2269N) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
WuXi Biologics (Cayman) Quick Ratio Related Terms
WuXi Biologics (Cayman) Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:2269N vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Quick Ratio distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
WuXi Biologics (Cayman)'s Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (MEX:2269N) has a Quick Ratio of 3.22 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on WuXi Biologics (Cayman) and its competitors. This is 18% above median its historical median of 2.74. Over the past decade, WuXi Biologics (Cayman)'s Quick Ratio has ranged from 0.94 to 4.18. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #758 out of 1416 companies in the Biotechnology industry, placing it in the top 53.5%.
Is WuXi Biologics (Cayman)'s Quick Ratio too high?
WuXi Biologics (Cayman)'s current Quick Ratio of 3.22 is 18% above median its 10-year median of 2.74. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 4.18. The Biotechnology industry median Quick Ratio is 3.60. WuXi Biologics (Cayman)'s value of 3.22 is 10.6% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #758 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #758 out of 1416 companies for Quick Ratio. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median Quick Ratio is 3.60. WuXi Biologics (Cayman)'s value of 3.22 is 10.6% below this benchmark. Historically, WuXi Biologics (Cayman)'s own Quick Ratio has ranged from 0.94 to 4.18 over the past decade. While the company's 10-year median is 2.74 vs. the industry median of 3.60, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Quick Ratio of 3.22 is 10.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Quick Ratio is 3.22, which is 18% above median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Quick Ratio of 3.22. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current Quick Ratio is 3.22, which is 18% above median its 10-year median of 2.74 and 10.6% below the Biotechnology industry median of 3.60. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Quick Ratio is 3.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.
Key valuation signals for MEX:2269N:
Quick Ratio: 3.22 (18% above median its 10-year median of 2.74)
GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
Industry Position: 10.6% below the Biotechnology median (#758 of 1416)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for MEX:2269N
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
